Literature DB >> 22613415

Stable knockdown of clusterin by vectorbased RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis.

J Li1, L Jia, P Zhao, Y Jiang, S Zhong, D Chen.   

Abstract

OBJECTIVE: Overexpression of the clusterin (CLU) gene occurs in breast cancer and is associated with lymph node metastasis. The present study explored the effect of CLU silencing on invasion and metastasis, and the relationship between CLU expression and the extracellular signal-regulated kinase (ERK) / matrix metalloproteinase-9 (MMP) signalling pathway in human breast cancer cells.
METHODS: A pcDNA3.1-based RNA interference approach was used to knockdown the CLU gene in MDA-231 cells (MDA-231-CLUi); control MDA-231 cells were transfected with an empty vector (MDA-231-Vec). Reverse transcription-polymerase chain reaction was used to assess CLU and MMP-9 mRNA levels, and Western blotting was used to analyse CLU, MMP-9 and ERK protein levels. Metastatic potential was evaluated using in vitro and in vivo models of invasion and metastasis.
RESULTS: Compared with MDA-231-Vec cells, the MDA-231-CLUi cells demonstrated reduced migration and invasion in vitro and decreased metastatic potential in vivo. Reintroduction and reexpression of the CLU gene into the MDA-231-CLUi cells restored the invasive phenotype. MMP-9 mRNA and protein levels were reduced in MDA-231-CLUi cells, and there was a correlation between activated ERK and CLU and MMP-9 protein levels.
CONCLUSION: CLU may regulate the aggressive behaviour of human breast cancer cells through modulation of ERK signalling and MMP9 expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22613415     DOI: 10.1177/147323001204000216

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  10 in total

1.  Plasma proteomics analysis of tamoxifen resistance in breast cancer.

Authors:  Keivan Majidzadeh-A; Javad Gharechahi
Journal:  Med Oncol       Date:  2013-10-26       Impact factor: 3.064

Review 2.  Protective molecular mechanisms of clusterin against apoptosis in cardiomyocytes.

Authors:  Rodrigo Martins Pereira; Rania A Mekary; Kellen Cristina da Cruz Rodrigues; Chadi Pellegrini Anaruma; Eduardo Rochete Ropelle; Adelino Sanchez Ramos da Silva; Dennys Esper Cintra; José Rodrigo Pauli; Leandro Pereira de Moura
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

Review 3.  The role and function of CLU in cancer biology and therapy.

Authors:  Yefei Zhang; Xiang Lv; Liming Chen; Yan Liu
Journal:  Clin Exp Med       Date:  2022-09-13       Impact factor: 5.057

Review 4.  Clusterin: a key player in cancer chemoresistance and its inhibition.

Authors:  Tomas Koltai
Journal:  Onco Targets Ther       Date:  2014-03-20       Impact factor: 4.147

5.  Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells.

Authors:  Qianjin Wang; Weiyan Cao; Quancai Su; Zimin Liu; Lin Zhang
Journal:  World J Surg Oncol       Date:  2014-04-26       Impact factor: 2.754

6.  Clusterin, a gene enriched in intestinal stem cells, is required for L1-mediated colon cancer metastasis.

Authors:  Beny Shapiro; Piera Tocci; Gal Haase; Nancy Gavert; Avri Ben-Ze'ev
Journal:  Oncotarget       Date:  2015-10-27

7.  Clusterin induced by N,N'-Dinitrosopiperazine is involved in nasopharyngeal carcinoma metastasis.

Authors:  Yuejin Li; Jinping Lu; Shan Zhou; Weiwei Wang; Gongjun Tan; Zhenlin Zhang; Zigang Dong; Tiebang Kang; Faqing Tang
Journal:  Oncotarget       Date:  2016-02-02

Review 8.  Apolipoproteins and cancer.

Authors:  Liwen Ren; Jie Yi; Wan Li; Xiangjin Zheng; Jinyi Liu; Jinhua Wang; Guanhua Du
Journal:  Cancer Med       Date:  2019-10-01       Impact factor: 4.452

Review 9.  Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer.

Authors:  Y Zhou; G Luo
Journal:  Clin Transl Oncol       Date:  2020-04-18       Impact factor: 3.405

10.  Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells.

Authors:  Hai Huang; Linna Wang; Mingyu Li; Xiaohui Wang; Lin Zhang
Journal:  World J Surg Oncol       Date:  2014-08-09       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.